Exclusive Content Related to 2025's Summit
Interview with Delix Therapeutics' CEO
The last 6 to 12 months have been a mixed bag - a few high-profile successes, but also many programs that have missed the mark. The current state of play, however, remains unchanged - there continues to be vast unmet need in the field of neuropsychiatry, and patients are waiting for better treatments...
Interview with Evecxia Therapeutics' CEO
Commercially and from an M\&A standpoint, recent successes include Cobenfy, Auvelity, Caplyta, and even Spravato. Those successes demonstrate the massive commercial potential in psychiatry. Cobenfy, Auvelity, and particularly Caplyta win on safety. Safety = scalability. Scalability = large markets. Large markets = blockbuster potential. All four drugs are based on clinical evidence. Cobenfy and Spravato use novel mechanisms of action, while Auvelity and Caplyta optimize on validated pharmacologies of yore. Unfortunately, in depression, there have been regrettable - yet not unexpected - trial failures...
Exclusive Content From the 2024 Summit
Interview with Engrail Therapeutics' VP of Translational Science and Clinical Development
Over the past several years, there has been an increase in the recognition of common psychiatric conditions as well as greater interest from patients to seek treatment. The negative stigma associated with many psychiatric conditions continues to decrease over time. We are also observing an increase in routine screening for psychiatric conditions. In June 2023, the United States Preventative Services Task Force (USPSTF) recommended annual screening for anxiety disorders in adults under 65 years old. This is an important step forward as it will boost diagnosis rates, particularly in the primary care setting. We believe a greater diagnosis rate will also increase the rate of treatment, improving overall patient outcomes...
Interview with the Senior Group Leader of the Broad Institute of MIT & Harvard
Our focus in the Stanley Center at Broad is on schizophrenia and bipolar disorder, and so the last 12 months have been particularly exciting largely because of the positive results around muscarinic receptor agonism (e.g., KarXT), which appears poised to become the first novel mechanism of action for schizophrenia treatment since the original antipsychotics were serendipitously discovered almost 70 years ago. It’s hard to overstate how exciting it would be to finally have a new class of drug for schizophrenia, not only for the impact on patients but also for the motivation and interest it generates with researchers and companies to see that success is possible in this space...
